, , and Status Predicts Prognosis in Glioma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Apr 18

PMID 30991699

Citations 14

Authors

Elise Deluche

Barbara Bessette

Stephanie Durand

Francois Caire

Valerie Rigau

Sandrine Robert

Alain Chaunavel

Lionel Forestier

Francois Labrousse

Marie-Odile Jauberteau

Karine Durand

Fabrice Lalloue

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to identify relevant biomarkers for the prognosis of glioma considering current molecular changes such as mutation and 1p19q deletion. Gene expression profiling was performed using the TaqMan Low Density Array and hierarchical clustering using 96 selected genes in 64 patients with newly diagnosed glioma. The expression dataset was validated on a large independent cohort from The Cancer Genome Atlas (TCGA) database. A differential expression panel of 26 genes discriminated two prognostic groups regardless of grade and molecular groups of tumors: Patients having a poor prognosis with a median overall survival (OS) of 23.0 ± 9.6 months (group A) and patients having a good prognosis with a median OS of 115.0 ± 6.6 months (group B) ( = 0.007). Hierarchical clustering of the glioma TCGA cohort supported the prognostic value of these 26 genes ( < 0.0001). Among these genes, and were identified as factors that can be associated with status and 1p/19q co-deletion to distinguish between prognostic groups of glioma from the TCGA cohort. Therefore, associated with seemed to be able to provide new information on glioma prognosis.

Citing Articles

Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications.

Mwale P, Hsieh C, Yen T, Jan J, Taliyan R, Yang C Mol Neurodegener. 2025; 20(1):7.

PMID: 39827337 PMC: 11742494. DOI: 10.1186/s13024-025-00801-8.

Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas.

Zhao D, Duan L, Juratli T, Shen F, Zhou L, Cui S Ann Clin Transl Neurol. 2024; 12(2):255-266.

PMID: 39556508 PMC: 11822795. DOI: 10.1002/acn3.52251.

Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.

Rautajoki K, Jaatinen S, Hartewig A, Tiihonen A, Annala M, Salonen I Acta Neuropathol Commun. 2023; 11(1):176.

PMID: 37932833 PMC: 10629206. DOI: 10.1186/s40478-023-01669-9.

Epithelial Membrane Protein-3 and Chitinase-3-like Protein-1 as New Prognostic Predictors of Glioma, a Two-Gene Study.

Shen K, Zhu J, Zhou S, Jin X, Zhai W, Sun L Curr Oncol. 2023; 30(10):8686-8702.

PMID: 37887529 PMC: 10605675. DOI: 10.3390/curroncol30100629.

Remarkable immune and clinical value of novel ferroptosis-related genes in glioma.

Gao X, Zhao J, Jia L, Zhang Q Sci Rep. 2022; 12(1):12854.

PMID: 35896732 PMC: 9329323. DOI: 10.1038/s41598-022-17308-7.

References

Nutt C, Mani D, Betensky R, Tamayo P, Cairncross J, Ladd C . Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003; 63(7):1602-7. View

Chao M . Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003; 4(4):299-309. DOI: 10.1038/nrn1078. View

Wadhwa S, Nag T, Jindal A, Kushwaha R, Mahapatra A, Sarkar C . Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma. J Biosci. 2003; 28(2):181-8. DOI: 10.1007/BF02706217. View

Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P . Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn. 2006; 8(4):433-43. PMC: 1867615. DOI: 10.2353/jmoldx.2006.060012. View

Giraud S, Bessette B, Boda C, Lalloue F, Petit D, Mathonnet M . In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats. Int J Oncol. 2006; 30(1):273-81. View

Assimakopoulou M, Kondyli M, Gatzounis G, Maraziotis T, Varakis J . Neurotrophin receptors expression and JNK pathway activation in human astrocytomas. BMC Cancer. 2007; 7:202. PMC: 2180182. DOI: 10.1186/1471-2407-7-202. View

Shirahata M, Iwao-Koizumi K, Saito S, Ueno N, Oda M, Hashimoto N . Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res. 2007; 13(24):7341-56. DOI: 10.1158/1078-0432.CCR-06-2789. View

Schmittgen T, Livak K . Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101-8. DOI: 10.1038/nprot.2008.73. View

Ermonval M, Petit D, Le Duc A, Kellermann O, Gallet P . Glycosylation-related genes are variably expressed depending on the differentiation state of a bioaminergic neuronal cell line: implication for the cellular prion protein. Glycoconj J. 2008; 26(4):477-93. DOI: 10.1007/s10719-008-9198-5. View

10.

Li A, Walling J, Ahn S, Kotliarov Y, Su Q, Quezado M . Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 2009; 69(5):2091-9. PMC: 2845963. DOI: 10.1158/0008-5472.CAN-08-2100. View

11.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F . Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27(25):4150-4. DOI: 10.1200/JCO.2009.21.9832. View

12.

Gravendeel L, Kouwenhoven M, Gevaert O, de Rooi J, Stubbs A, Duijm J . Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009; 69(23):9065-72. DOI: 10.1158/0008-5472.CAN-09-2307. View

13.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

14.

Noushmehr H, Weisenberger D, Diefes K, Phillips H, Pujara K, Berman B . Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17(5):510-22. PMC: 2872684. DOI: 10.1016/j.ccr.2010.03.017. View

15.

Ku B, Lee Y, Ryu J, Jeong J, Choi J, Eun K . CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells. Int J Cancer. 2010; 128(6):1316-26. DOI: 10.1002/ijc.25466. View

16.

Giraud S, Loum E, Bessette B, Mathonnet M, Lalloue F . P75 neurotrophin receptor is sequestered in the Golgi apparatus of the U-87 MG human glioblastoma cell line. Int J Oncol. 2010; 38(2):391-9. DOI: 10.3892/ijo.2010.862. View

17.

Faibish M, Francescone R, Bentley B, Yan W, Shao R . A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther. 2011; 10(5):742-51. PMC: 3091949. DOI: 10.1158/1535-7163.MCT-10-0868. View

18.

Cheray M, Petit D, Forestier L, Karayan-Tapon L, Maftah A, Jauberteau M . Glycosylation-related gene expression is linked to differentiation status in glioblastomas undifferentiated cells. Cancer Lett. 2011; 312(1):24-32. DOI: 10.1016/j.canlet.2011.07.027. View

19.

Wang F, Flanagan J, Su N, Wang L, Bui S, Nielson A . RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2011; 14(1):22-9. PMC: 3338343. DOI: 10.1016/j.jmoldx.2011.08.002. View

20.

Turcan S, Rohle D, Goenka A, Walsh L, Fang F, Yilmaz E . IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012; 483(7390):479-83. PMC: 3351699. DOI: 10.1038/nature10866. View